Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial

Clinical Trials

Volumn 13, Issue 3, 2016, Pages 331-337

  Basch, Ethan ^a,b   Wood, William A ^b   Schrag, Deborah ^c   Sima, Camelia S ^a   Shaw, Mary ^a   Rogak, Lauren J ^a   Kris, Mark G ^d   Shouery, Marwan ^a   Bennett, Antonia ^b   Atkinson, Thomas ^a   Catherine Pietanza, M ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

adverse event; clinical trial; drug development; Patient reported outcome; toxicity

Indexed keywords

BEVACIZUMAB; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER RESEARCH; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DISEASE SEVERITY; DYSPNEA; EPIPHORA; EPISTAXIS; FATIGUE; FEASIBILITY STUDY; FEMALE; HOARSENESS; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG CANCER; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; PAIN; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRIORITY JOURNAL; RATING SCALE; SELF REPORT; SENSORY NEUROPATHY; SIDE EFFECT; STATISTICAL ANALYSIS; STOMATITIS; TREATMENT OUTCOME; INFORMATION DISSEMINATION; LUNG TUMOR; MIDDLE AGED; PATIENT-REPORTED OUTCOME; PERSONNEL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; INFORMATION DISSEMINATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PATIENT REPORTED OUTCOME MEASURES; PEMETREXED; RESEARCH PERSONNEL; SELF REPORT;

EID: 84966546684     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774515615540     Document Type: Article

References (25)

1. Reilly CM, Bruner DW, Mitchell SA, et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer 2013; 21: 1525-1550.
2. Henry DH, Viswanathan HN, Elkin EP, et al. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer 2008; 16: 791-801.
3. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE)., version 4.0 (NIH publication # 09-7473, Published 29 May 2009; Revised version 4.03 14 June 2010), http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf (. accessed 1 May 2015).
4. Schag CC, Heinrich RL, Ganz PA,. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2: 187-193.
5. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004; 22: 3485-3490.
6. Laugsand EA, Sprangers MA, Bjordal K, et al. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes 2010; 8: 104.
7. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 2006; 7: 903-909.
8. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 2009; 101: 1624-1632.
9. Pakhomov SV, Jacobsen SJ, Chute CG, et al. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 2008; 14: 530-539.
10. Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res 2012; 21: 1159-1164.
11. Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 2012; 30: 1980-1988.
12. Cleeland CS, Wang XS, Shi Q, et al. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol 2011; 29: 994-1000.
13. Gilbert JE, Howell D, King S, et al. Quality improvement in cancer symptom assessment and control: the Provincial Palliative Care Integration Project (PPCIP). J Pain Symptom Manage 2012; 43: 663-678.
14. Valderas JM, Kotzeva A, Espallargues M, et al. The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res 2008; 17: 179-193.
15. Chen J, Ou L, Hollis SJ,. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 2013; 13: 211.
16. Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 2014; 32: 1480-1501.
17. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 2002; 288: 3027-3034.
18. Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 2005; 23: 3552-3561.
19. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 2004; 22: 714-724.
20. Berry DL, Blumenstein BA, Halpenny B, et al. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol 2011; 29: 1029-1035.
21. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106 (9): dju244.
22. Basch E, Artz D, Iasonos A, et al. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc 2007; 14: 264-268.
23. Pietanza MC, Basch EM, Lash A, et al. Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. J Clin Oncol 2013; 31: 2004-2009.
24. Santana MJ, Feeny D, Johnson JA, et al. Assessing the use of health-related quality of life measures in the routine clinical care of lung-transplant patients. Qual Life Res 2010; 19: 371-379.
25. Chung AE, Basch E,. Incorporating the patient's voice into electronic health records through patient-reported outcomes as the "review of systems.". J Am Med Inform Assoc 2015; 22: 914-916.